The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair

Activin A, a member of the transforming growth factor-β superfamily of cytokines, is a critical controller of inflammation, immunity and fibrosis. It is rapidly released into the blood following a lipopolysaccharide challenge in experimental animals, through activation of the Toll-like receptor 4 si...

Full description

Saved in:
Bibliographic Details
Published inMolecular and cellular endocrinology Vol. 359; no. 1-2; pp. 101 - 106
Main Authors de Kretser, David M., O’Hehir, Robyn E., Hardy, Charles L., Hedger, Mark P.
Format Journal Article
LanguageEnglish
Published Ireland Elsevier Ireland Ltd 15.08.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Activin A, a member of the transforming growth factor-β superfamily of cytokines, is a critical controller of inflammation, immunity and fibrosis. It is rapidly released into the blood following a lipopolysaccharide challenge in experimental animals, through activation of the Toll-like receptor 4 signalling pathway. Blocking activin action by pre-treatment with its binding protein, follistatin, modifies the inflammatory cytokine cascade, and reduces the severity of the subsequent inflammatory response and mortality. Likewise, high serum levels of activin A are predictive of death in patients with septicaemia. However, activin A has complex immunomodulatory actions. It is produced by inflammatory macrophages, but can regulate either pro- or anti-inflammatory responses in these cells, depending on their prior activation status. Activin A is also produced by Th2 cells, and stimulates antibody production by B cells and the development of regulatory T cells. Production of activin A during inflammatory responses stimulates fibrosis and tissue remodelling, and follistatin inhibits these actions of activin A. The modulation of activin by follistatin may represent an important therapeutic target for the modulation and amelioration of inflammatory and fibrotic disorders.
Bibliography:http://dx.doi.org/10.1016/j.mce.2011.10.009
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Feature-1
ISSN:0303-7207
1872-8057
DOI:10.1016/j.mce.2011.10.009